| INACTIVE INGREDIENT | These highlights do not include all the information needed to use ATORVASTATIN calcium tablets safely and effectively. See full prescribing information for ATORVASTATIN calcium tablets. ATORVASTATIN calcium tablets for oral administration Initial U.S. Approval: 1996 | 1 |
| INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM | 2 |
| INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM | 5 |
| ACTIVE INGREDIENT | GoutFlex Gout Symptom Formula | 1 |
| INACTIVE INGREDIENT | Drug Facts | 1 |
| INACTIVE INGREDIENT | Ceftazidime for Injection, USP | 12 |
| INACTIVE INGREDIENT | Ceftazidime for Injection, USP | 12 |
| INACTIVE INGREDIENT | BJWC Nicotine Gum Drug Facts | 4 |
| INACTIVE INGREDIENT | SuperValu Inc. Nicotine Gum Drug Facts | 4 |
| INACTIVE INGREDIENT | Kroger Co. Nicotine Polacrilex Gum 2 mg (nicotine) Drug Facts | 2 |
| INACTIVE INGREDIENT | SuperValu Inc. Nicotine Gum Drug Facts | 4 |
| INACTIVE INGREDIENT | Kroger Co. Nicotine Polacrilex Gum 2 mg (nicotine) Drug Facts | 2 |
| INACTIVE INGREDIENT | Kroger Co. Nicotine Gum Drug Facts | 2 |
| INACTIVE INGREDIENT | Supervalu Inc. Nicotine Gum Drug Facts | 4 |
| INACTIVE INGREDIENT | Metformin Hydrochloride Extended-release Tablets, USP | 4 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use PANTOPRAZOLE sodium delayed-release tablets, USP safely and effectively. See full prescribing information for PANTOPRAZOLE sodium delayed-release tablets, USP. PANTOPRAZOLE sodium delayed-release tablets, USP, for oral administration Initial U.S. approval: 2000 | 11 |
| INACTIVE INGREDIENT | BJWC Nicotine Polacrilex Gum 2 mg (nicotine) Drug Facts | 4 |
| ACTIVE INGREDIENT | Drug Facts | 1 |
| ACTIVE INGREDIENT | Drug Facts | 1 |
| ACTIVE INGREDIENT | Gout Symptom Relief™ | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. PANTOPRAZOLE sodium delayed-release tablets USP, for oral administration Initial U.S. approval: 2000 | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE Sodium delayed-release tablets USP for oral use Initial U.S. approval: 2000 | 1 |
| INACTIVE INGREDIENT | CVS Pharmacy, Inc. Nicotine Gum Drug Facts | 2 |
| INACTIVE INGREDIENT | Metformin Hydrochloride Extended-release Tablets, USP | 4 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets USP safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets USP. PANTOPRAZOLE Sodium Delayed-Release Tablets USP for oral use Initial U.S. Approval: 2000 | 2 |
| INACTIVE INGREDIENT | Kroger Co. Nicotine Polacrilex Lozenge 4 mg (nicotine) Drug Facts | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use atorvastatin calcium tablets safely and effectively. See full prescribing information for atorvastatin calcium tablets. Atorvastatin Calcium Tablets for oral administration Initial U.S. Approval: 1996 | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. Pantoprazole Sodium Delayed-Release Tablets, USP Initial U.S. approval: 2000 | 1 |
| ACTIVE INGREDIENT | Gout Symptom Reliever | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE sodium delayed-release tablets USP for oral use Initial U.S. Approval: 2000 | 1001 |
| INACTIVE INGREDIENT | Package Labeling | 1 |
| INACTIVE INGREDIENT | Package Labeling | 1 |
| INACTIVE INGREDIENT | McKesson Nicotine Polacrilex Gum USP, 2 mg (nicotine) Drug Facts | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets. PANTOPRAZOLE SODIUM delayed-release tablets Initial U.S. approval: 2000 | 1 |
| INACTIVE INGREDIENT | Bayer ® Advanced Aspirin 325 mg Coated Tablet | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets. PANTOPRAZOLE SODIUM delayed-release tablets Initial U.S. approval: 2000 | 3 |
| ACTIVE INGREDIENT | 9b73e20a-4ac8-4111-a69e-17ee1bca8e65 | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. PANTOPRAZOLE sodium delayed-release tablets, USP, for oral use Initial U.S. Approval: 2000 | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use ATORVASTATIN CALCIUM safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM. ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM) TABLET, FILM COATED for ORAL use. Initial U.S. Approval: 2012 | 3 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM. PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) TABLET for ORAL use. Initial U.S. Approval: 2007 | 3 |
| ACTIVE INGREDIENT | Overly-Sensitive™ | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use atorvastatin calcium tablets safely and effectively. See full prescribing information for atorvastatin calcium tablets. Atorvastatin Calcium Tablets for oral administration Initial U.S. Approval: 1996 | 4 |
| ACTIVE INGREDIENT | Climate Adaptation Hot and Dry™ | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pravastatin sodium safely and effectively. See full prescribing information for pravastatin sodium tablets. Initial U.S. Approval: 1991 | 1 |
| INACTIVE INGREDIENT | Handy Solutions GENUINE ASPIRIN BAYER | 1 |
| ACTIVE INGREDIENT | Morale Remedy No. 19 | 1 |
| ACTIVE INGREDIENT | AllergyEase Food and Chemical | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use atorvastatin calcium tablets safely and effectively. See full prescribing information for atorvastatin calcium tablets. Atorvastatin Calcium Tablets for oral administration Initial U.S. Approval: 1996 | 3 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use atorvastatin calcium tablets safely and effectively. See full prescribing information for atorvastatin calcium tablets. Atorvastatin Calcium Tablets for oral administration Initial U.S. Approval: 1996 | 1 |
| ACTIVE INGREDIENT | Drug Facts | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use Meropenem for Injection safely and effectively. See full prescribing information for Meropenem for Injection. Meropenem for Injection Initial U.S. Approval: 1996 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible b | 17 |
| INACTIVE INGREDIENT | Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% (Sterile) | 2 |
| INACTIVE INGREDIENT | SHISEIDO SUN PROTECTION FOUNDATION TRANSLUCENT | 1 |
| ACTIVE INGREDIENT | Allergy Food and Chemical Relief | 1 |
| ACTIVE INGREDIENT | AgoraFear Relief | 1 |
| ACTIVE INGREDIENT | DRUG FACTS | 1 |
| ACTIVE INGREDIENT | Homeopathic Tension Headache Formula | 1 |
| INACTIVE INGREDIENT | SHISEIDO SUN PROTECTION FOUNDATION | 1 |
| ACTIVE INGREDIENT | Calm Remedy Water ® | 3 |
| ACTIVE INGREDIENT | Control Remedy Water ® | 3 |
| INACTIVE INGREDIENT | Drug Facts | 1 |
| INACTIVE INGREDIENT | Drug Facts | 1 |
| INACTIVE INGREDIENT | Tri-Sprintec ® (norgestimate and ethinyl estradiol tablets - triphasic regimen) PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. Rx only | 1 |
| INACTIVE INGREDIENT | SHISEIDO THE MAKEUP STICK FOUNDATION Control Color | 1 |
| INACTIVE INGREDIENT | SHISEIDO THE MAKEUP STICK FOUNDATION | 1 |
| ACTIVE INGREDIENT | Acid Detox | 3 |
| ACTIVE INGREDIENT | Attention and Learning Enhancement | 3 |
| ACTIVE INGREDIENT | Good Mood Enhancer | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE sodium delayed-release tablets USP for oral use Initial U.S. Approval: 2000 | 2 |
| INACTIVE INGREDIENT | 8a023942-01e8-4849-aa3c-1a640ffc7fd3 | 7 |
| INACTIVE INGREDIENT | Tri-Sprintec ® (norgestimate and ethinyl estradiol tablets - triphasic regimen) PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. Rx only | 1 |
| INACTIVE INGREDIENT | Tri-Sprintec ® (norgestimate and ethinyl estradiol tablets - triphasic regimen) PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. Rx only | 1 |
| ACTIVE INGREDIENT | Lymphatic Drainer | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX. PROTONIX (pantoprazole sodium) delayed-release tablets PROTONIX (pantoprazole sodium) for delayed-release oral suspension Initial U.S. approval: 2000 | 1 |
| ACTIVE INGREDIENT | Connective Tissue | 5 |
| ACTIVE INGREDIENT | Edema | 3 |
| ACTIVE INGREDIENT | Warts - Moles - Skin Tags | 3 |
| ACTIVE INGREDIENT | Candidiasis~Yeast | 2 |
| ACTIVE INGREDIENT | Lymphatic Drainer | 2 |
| ACTIVE INGREDIENT | Cold Sore Complex | 1 |
| ACTIVE INGREDIENT | Connective Tissue | 1 |
| ACTIVE INGREDIENT | Edema | 1 |
| INACTIVE INGREDIENT | Metformin Hydrochloride Extended - Release Tablets | 2 |
| ACTIVE INGREDIENT | Indigestion - Gas | 2 |
| ACTIVE INGREDIENT | Indigestion - Gas | 2 |
| ACTIVE INGREDIENT | Throat Care | 2 |
| ACTIVE INGREDIENT | Throat Care | 2 |
| ACTIVE INGREDIENT | Warts - Moles - Skin Tags | 2 |
| ACTIVE INGREDIENT | Tummy Upset | 1 |
| ACTIVE INGREDIENT | Warts - Moles - Skin Tags | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets, USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets, USP. Pantoprazole Sodium Delayed-Release Tablets, USP Initial U.S. approval: 2000 | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE sodium delayed-release tablets USP for oral use Initial U.S. Approval: 2000 | 1 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX. PROTONIX (pantoprazole sodium) delayed-release tablets PROTONIX (pantoprazole sodium) for delayed-release oral suspension Initial U.S. approval: 2000 | 1 |
| ACTIVE INGREDIENT | Storm Stress Feline | 2 |
| INACTIVE INGREDIENT | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets. PANTOPRAZOLE SODIUM delayed-release tablets Initial U.S. approval: 2000 | 1 |
| ACTIVE INGREDIENT | Allergy Composition | 3 |
| INACTIVE INGREDIENT | Metformin Hydrochloride Extended - Release Tablets | 1 |
| INACTIVE INGREDIENT | Pantoprazole Sodium Delayed-Release Tablets | 1 |
| INACTIVE INGREDIENT | 8459857e-1a52-45de-81e6-e06ce18508bb | 2 |
| INACTIVE INGREDIENT | PROTONIX DELAYED-RELEASE (PANTOPRAZOLE SODIUM) TABLET, DELAYED RELEASE [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC] | 3263 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1000 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1000 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1000 |
| INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE [BRYANT RANCH PREPACK] | 1000 |
| INACTIVE INGREDIENT | PRAVASTATIN SODIUM TABLET [BRYANT RANCH PREPACK] | 1000 |
| INACTIVE INGREDIENT | PROTONIX DELAYED-RELEASE (PANTOPRAZOLE SODIUM) TABLET, DELAYED RELEASE PROTONIX DELAYED-RELEASE (PANTOPRAZOLE SODIUM) GRANULE, DELAYED RELEASE [WYETH PHARMACEUTICALS INC., A SUBSIDIARY OF PFIZER INC.] | 26 |
| INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE [JUBILANT CADISTA PHARMACEUTICALS INC.] | 18 |
| INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM DELAYED-RELEASE (PANTOPRAZOLE SODIUM) TABLET, DELAYED RELEASE [WYETH PHARMACEUTICALS INC., A SUBSIDIARY OF PFIZER INC.] | 15 |
| INACTIVE INGREDIENT | MERREM IV (MEROPENEM) INJECTION [ASTRAZENECA PHARMACEUTICALS LP] | 14 |
| INACTIVE INGREDIENT | TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] | 14 |
| INACTIVE INGREDIENT | FUZEON (ENFUVIRTIDE) KIT [GENENTECH, INC.] | 13 |
| INACTIVE INGREDIENT | NICORETTE WHITE ICE MINT (NICOTINE POLACRILEX) GUM, CHEWING NICORETTE ORIGINAL (NICOTINE POLACRILEX) GUM, CHEWING NICORETTE CINNAMON SURGE (NICOTINE POLACRILEX) GUM, CHEWING NICORETTE FRESH MINT (NICOTINE POLACRILEX) GUM, CHEWING NICORETTE MINT (NICOTINE POLACRILEX) GUM, CHEWING NICORETTE SPEARMINT BURST (NICOTINE POLACRILEX) GUM, CHEWING [GLAXOSMITHKLINE CONSUMER HEALTHCARE LP] | 13 |
| INACTIVE INGREDIENT | TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] | 13 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.] | 12 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [MYLAN PHARMACEUTICALS INC.] | 12 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.] | 12 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [APOTEX CORP.] | 11 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [INTERNATIONAL LABORATORIES, INC.] | 11 |
| INACTIVE INGREDIENT | ATORVASTATIN CALCIUM TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.] | 11 |
| INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE [TEVA PHARMACEUTICALS USA INC] | 11 |
pubchem.ncbi.nlm.nih.gov/compound/10340
mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=36685
ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47721
precision.fda.gov/uniisearch/srs/unii/45P3261C7T
commonchemistry.cas.org/results?q=207-838-8